Table 2.
Characteristics of included cutaneous immune-related adverse events.
| Terms | n | Percentage of all patients (%) | Percentage of cirAEs (%) |
|---|---|---|---|
| CirAEs | 24,814 | 12.5 | – |
| Subtypes | |||
| Maculopapular | 8,201 | 4.1 | 33.0 |
| Pruritus | 6,941 | 3.5 | 28.0 |
| Unspecified rash | 1,299 | 0.7 | 5.2 |
| Vitiligo | 640 | 0.3 | 2.6 |
| Psoriasis | 551 | 0.3 | 2.2 |
| Skin eruption | 390 | 0.2 | 1.6 |
| STS/JEN | 378 | 0.2 | 1.5 |
| Eczema | 236 | 0.1 | 1.0 |
| Lichenoid | 228 | 0.1 | 0.9 |
| BP | 113 | 0.1 | 0.5 |
| Mucositis | 132 | 0.1 | 0.5 |
| RCCEP | 104 | 0.1 | 0.4 |
| Othersa | 314 | 0.2 | 1.3 |
| Grade | |||
| 1~2 | 12,659 | 6.4 | 51.0 |
| 3~4 | 634 | 0.3 | 2.6 |
| NR | 11,521 | 5.8 | 46.4 |
| Occurrence time (days) | Range | Median | IQR |
| 2~1065 | 23~212 | [2~42, 84~1015] | |
CirAEs, cutaneous immune-related adverse events. SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis. BP, bullous pemphigoid. RCCEP, reactive cutaneous capillary endothelial proliferation. NR, not reported. IQR, Interquartile range. aOthers types including granulomatous, erythema multiforme, DRESS, morbilliform, urticarial, acneiform eruption, mucositis, panniculitis, sweet syndrome, severe cutaneous adverse reaction, alopecia, xerosis, arcoidosis, Grove’s disease.